Anti-inflammatory properties of drugs acting on the renin-angiotensin system

Area of Science:

• Cardiovascular Science
• Renal Science
• Inflammation Biology

Background:

• The renin-angiotensin system (RAS) is implicated in cardiovascular and renal diseases.
• Angiotensin II (Ang II), the main RAS effector, promotes inflammation via cytokines, chemokines, and reactive oxygen species.
• Ang II contributes to vascular inflammation, endothelial dysfunction, fibrosis, atherosclerosis, and chronic kidney disease.

Purpose of the Study:

• To review the role of the RAS, particularly Ang II, in initiating and maintaining inflammatory processes.
• To summarize evidence for RAS-targeting drugs in preventing or modulating inflammation.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of the mechanisms by which Ang II induces inflammation.
• Evaluation of the impact of RAS blockade on inflammatory processes.

Main Results:

• RAS activation and Ang II are key drivers of inflammation in cardiovascular and renal pathologies.
• Ang II mediates vascular inflammation, endothelial dysfunction, fibrosis, and atherosclerotic plaque destabilization.
• RAS blockade significantly reduces cardiovascular and renal morbidity and mortality, partly by mitigating inflammation.

Conclusions:

• The RAS plays a critical role in initiating and perpetuating inflammation in cardiovascular and renal diseases.
• Drugs targeting the RAS demonstrate efficacy in preventing or modulating these inflammatory processes.
• RAS inhibition offers therapeutic benefits beyond blood pressure control by reducing inflammation.